ProCE Banner Activity

CME

New Agents and Evolving Strategies in Prostate Cancer: Focus on Castration-Sensitive Disease

Multimedia
In this on-demand webcast from a live webinar, Michael S. Cookson, MD, MMHC, FACS; David F. Jarrard, MD; and Atish Choudhury, MD, PhD, review the current data on managing castration-sensitive prostate cancer including data from the 2022 ASCO Genitourinary Cancers Symposium.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: March 14, 2022

Expiration: March 13, 2023

No longer available for credit.

Share

Faculty

Atish Choudhury

Atish Choudhury, MD, PhD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Senior Physician
Medical Oncology
Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Michael S. Cookson

Michael S. Cookson, MD, MMHC, FACS

Professor and Chair
Department of Urology
The University of Oklahoma Health Sciences Center, College of Medicine
Urologic Oncologist
OU Health Stephenson Cancer Center, Prostate & Urologic Cancers Clinic
OU Health
Oklahoma City, Oklahoma

David F. Jarrard

David F. Jarrard, MD

Professor and Vice Chair
Department of Urology
John P. Livesey Chair in Urologic Oncology
Associate Director for Translational Research
Carbone Cancer Center
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Myovant Sciences Inc

Pfizer, Inc.

Target Audience

This program is intended for oncologists and other healthcare professionals who care for patients with prostate cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Compare the mechanism of action, cardiovascular risk, and overall toxicity profiles associated with all approved systemic therapies for CSPC
  • Apply cardioprotective strategies to reduce risk in patients with prostate cancer receiving ADT
  • Plan optimal, individualized sequential therapeutic strategies for nonmetastatic or metastatic CSPC, considering all available agents, clinical data, and expert recommendations
  • Counsel patients on available therapies, taking into consideration patient preferences and comorbidities regarding differences in administration and safety profiles

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Atish Choudhury, MD, PhD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Senior Physician
Medical Oncology
Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Atish Choudhury, MD, PhD, has disclosed that he has received consulting fees from Astellas, AstraZeneca, Bayer, Blue Earth, and Lilly.

Michael S. Cookson, MD, MMHC, FACS

Professor and Chair
Department of Urology
The University of Oklahoma Health Sciences Center, College of Medicine
Urologic Oncologist
OU Health Stephenson Cancer Center, Prostate & Urologic Cancers Clinic
OU Health
Oklahoma City, Oklahoma

Michael S. Cookson, MD, MMHC, FACS, has disclosed that he has received consulting fees from Astellas, Bayer, Janssen, Merck, Myovant Sciences, Pacific Edge Diagnostics, Prokarium, Propella, and TesoRx; funds for research support from Bayer HealthCare AG and Ferring; and other fees (reviewer of abstracts) from BioPharm Communications.

David F. Jarrard, MD

Professor and Vice Chair
Department of Urology
John P. Livesey Chair in Urologic Oncology
Associate Director for Translational Research
Carbone Cancer Center
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin

David F. Jarrard, MD, has no relevant conflicts of interest to report.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no relevant conflicts of interest to report.

Kemi Obajimi, PhD

Scientific Director

Kemi Obajimi, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 14, 2022, through March 13, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, confidence, and competence of learners to integrate new agents and recent findings into the treatment of patients with prostate cancer.